Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer-Reference-Cited by-同舟云学术

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

Published:2010-12-15 Issue:62 Volume:2 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Weiss Jonathan¹,Sos Martin L.¹,Seidel Danila¹²,Peifer Martin¹,Zander Thomas³,Heuckmann Johannes M.¹,Ullrich Roland T.¹,Menon Roopika⁴,Maier Sebastian⁴,Soltermann Alex⁵,Moch Holger⁵,Wagener Patrick⁶,Fischer Florian¹,Heynck Stefanie¹,Koker Mirjam¹,Schöttle Jakob¹,Leenders Frauke¹²,Gabler Franziska¹²,Dabow Ines¹²,Querings Silvia¹,Heukamp Lukas C.⁷,Balke-Want Hyatt¹,Ansén Sascha³,Rauh Daniel⁸,Baessmann Ingelore⁹,Altmüller Janine⁹,Wainer Zoe¹⁰,Conron Matthew¹⁰,Wright Gavin¹⁰,Russell Prudence¹¹,Solomon Ben¹²,Brambilla Elisabeth¹³¹⁴,Brambilla Christian¹³¹⁴,Lorimier Philippe¹³,Sollberg Steinar¹⁵,Brustugun Odd Terje¹⁶¹⁷,Engel-Riedel Walburga¹⁸,Ludwig Corinna¹⁸,Petersen Iver¹⁹,Sänger Jörg²⁰,Clement Joachim²¹,Groen Harry²²,Timens Wim²³,Sietsma Hannie²³,Thunnissen Erik²⁴,Smit Egbert²⁵,Heideman Daniëlle²⁴,Cappuzzo Federico²⁶,Ligorio Claudia²⁷,Damiani Stefania²⁷,Hallek Michael³²⁸,Beroukhim Rameen²⁹³⁰³¹³²,Pao William³³,Klebl Bert³⁴,Baumann Matthias³⁴,Buettner Reinhard⁷,Ernestus Karen³⁵,Stoelben Erich¹⁸,Wolf Jürgen²³,Nürnberg Peter⁸²⁸,Perner Sven⁴,Thomas Roman K.¹²³⁸

Affiliation:

1. Max Planck Institute for Neurological Research, Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, 50931 Cologne, Germany.

2. Laboratory of Translational Cancer Genomics, Center of Integrated Oncology Köln-Bonn, University of Cologne, 50924 Cologne, Germany.

3. Department I of Internal Medicine and Center of Integrated Oncology Köln-Bonn, University of Cologne, 50924 Cologne, Germany.

4. Institute of Pathology, Comprehensive Cancer Center, University Hospital Tübingen, 72076 Tübingen, Germany.

5. Institute for Surgical Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.

6. Department of Surgery, Weill Medical College, Cornell University, New York, NY 10065, USA.

7. Institute of Pathology, University of Bonn, 53123 Bonn, Germany.

8. Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany.

9. Cologne Center for Genomics and Institute for Genetics, University of Cologne, 50931 Cologne, Germany.

10. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, 3002 Victoria, Australia.

11. Department of Pathology, St. Vincent’s Hospital, Melbourne, 3065 Victoria, Australia.

12. Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, 3002 Victoria, Australia.

13. Department of Pathology, Université Joseph Fourier, 38041 Grenoble, France.

14. Institut Albert Bonniot INSERM U823, Université Joseph Fourier, 38042 Grenoble, France.

15. Department of Thoracic Surgery, Rikshospitalet, Oslo University Hospital, 0027 Oslo, Norway.

16. Department of Radiation Biology, Norwegian Radium Hospital, N-0310 Oslo, Norway.

17. Department of Oncology, Radiumhospitalet, Oslo University Hospital, N-0310 Oslo, Norway.

18. Thoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH, 51109 Cologne, Germany.

19. Institute of Pathology, Jena University Hospital, Friedrich-Schiller-University, 07743 Jena, Germany.

20. Institute for Pathology Bad Berka, 99438 Bad Berka, Germany.

21. Department for Internal Medicine II, University Clinic Jena, Friedrich-Schiller University, 07740 Jena, Germany.

22. Department of Pulmonary Diseases, University Medical Centre Groningen, 9713 GZ Groningen, Netherlands.

23. Department of Pathology, University Medical Centre Groningen, 9713 GZ Groningen, Netherlands.

24. Department of Pathology, VU University Medical Center Amsterdam, 1007 MB Amsterdam, Netherlands.

25. Department of Pulmonary Diseases, VU University Medical Center Amsterdam, 1007 MB Amsterdam, Netherlands.

26. Department of Medical Oncology, Ospedale Civile, 57100 Livorno, Italy.

27. Department of Haematology and Oncologic Science, University Hospital Bologna, 40138 Bologna, Italy.

28. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, 50931 Cologne, Germany.

29. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

30. Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA.

31. Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

32. Cancer Program, Broad Institute, Cambridge, MA 02115, USA.

33. Vanderbilt-Ingram Cancer Center, Nashville, TN 37212, USA.

34. Lead Discovery Center GmbH, 44227 Dortmund, Germany.

35. Department of Pathology, Hospital Merheim, Kliniken der Stadt Köln gGmbH, 51109 Cologne, Germany.

Abstract

FGFR1 amplification provides a therapeutic target for squamous cell lung cancer, which is resistant to other targeted lung cancer drugs.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference35 articles.

1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

4. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

5. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by 700 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

2. Predictive insights into plant-based compounds as fibroblast growth factor receptor 1 inhibitors: a combined molecular docking and dynamics simulation study;Journal of Biomolecular Structure and Dynamics;2024-04-26

3. Clinical Efficacy and Mechanism of Action of Recently FDA Approved Anticancer Drugs: An Updated Review;Current Cancer Therapy Reviews;2024-04-09

4. Oncogene alterations in non-small cell lung cancer with FGFR1 amplification—novel approach to stratify patients who benefit from FGFR inhibitors;Translational Lung Cancer Research;2024-03

5. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions;Nature Reviews Clinical Oncology;2024-02-29